

corresponding polynucleotide sequence.

Applicants further submit that the claims of Groups I and III share common technical feature in that the claims directed to antibodies (Group III) define in part antibodies that recognize the polypeptide sequence of SEQ ID NO: 5 and the antibodies are defined in the claims by reference to the polypeptide antigen, a conventional practice for defining antibodies. Thus, the claims directed to antibodies and polypeptides share unity of invention.


Based on the foregoing, it is submitted that all the claims of the present application share unity of invention via common technical feature and should be examined together. Applicants respectfully request reconsideration of the restriction requirement and at a minimum simultaneous examination of claims 63-66, 67, 72, 83 and 84 to the extent relevant to the sequence as set forth in SEQ ID NO: 5.

Conclusion

This Response is accompanied by a Petition for Extension of Time and the fee of \$110.00 (one month) for a large entity pursuant to 37 C.F.R. § 1.17(a)(1).

If this amount is incorrect, please charge any fees or credit any overpayments under the foregoing rules to Deposit Account No. 07-1969.

Respectfully submitted,



Heeja Yoo-Warren
Reg. No. 45,495

GREENLEE, WINNER AND SULLIVAN, P.C.
5370 Manhattan Circle, Suite 201
Boulder, CO 80303
Telephone: (303) 499-8080 / Facsimile: (303) 499-8089
E-mail: winner@greenwin.com
Attorney Docket No. 20-02
nk: November 14, 2003